세계의 비뇨생식기 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Genitourinary Drugs Market is presumed to reach the market size of nearly USD 41.22 Billion by 2032 from USD 35.23 Billion in 2023 with a CAGR of 1.76% under the study period 2024-2032.

Genitourinary drugs are pharmaceutical agents designed to treat disorders & diseases affecting the urinary tract and reproductive organs. These drugs encompass various therapeutic categories, including antibiotics, antivirals, antifungals, hormones, and immunosuppressants. They are used to manage conditions such as urinary tract infections (UTIs), erectile dysfunction, benign prostatic hyperplasia (BPH), infertility, sexually transmitted infections (STIs), and various cancers of the genitourinary system. Based on the disease or disorder being treated, these drugs may target pathogens, modulate hormone levels, reduce inflammation, or inhibit cancer cell growth.

MARKET DYNAMICS

The genitourinary drugs market is driven by the increasing prevalence of genitourinary disorders, advancements in drug development, and evolving healthcare demographics. The rising incidence of genitourinary conditions such as UTIs, prostate disorders, and sexually transmitted diseases propels the demand for effective pharmaceutical treatments. Rapid urbanization, lifestyle changes, and aging populations contribute to a higher disease burden, necessitating continuous innovation in genitourinary drug therapies. Moreover, advancements in drug delivery systems, personalized medicine approaches, and biomarker identification enhance treatment efficacy and patient outcomes. Targeted therapies for conditions like prostate cancer and erectile dysfunction are expanding treatment options and improving the quality of life for affected individuals. Furthermore, growing healthcare expenditure and investments in urological research drive market expansion. Pharmaceutical companies focus on developing novel therapies & expanding indications for existing drugs to address unmet medical needs in genitourinary medicine. Increasing awareness about reproductive health, proactive screening initiatives, and patient education programs also foster genitourinary drugs market growth. Healthcare providers and policymakers prioritize preventive care and early intervention strategies, supporting market uptake of genitourinary drugs. However, stringent regulatory requirements for drug approval and patent expirations challenge market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Genitourinary Drugs. The growth and trends of Genitourinary Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Genitourinary Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

• Prostate Cancer
• Ovarian Cancer
• Bladder Cancer
• Cervical Cancer
• Renal Cancer
• Erectile Dysfunction
• Urinary Tract Infections
• Urinary Incontinence & Overactive Bladder
• Sexually Transmitted Diseases
• Interstitial Cystitis
• Haematuria
• Benign Prostatic Hyperplasia

By Product

• Urologicals
• Hormonal Therapy
• Gynecological
• Anti-Infectives
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Genitourinary Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genitourinary Drugs market include Abbott, Bristol-Myers Squibb Co., Novartis AG, Genentech Inc., F. Hoffmann-La RocheLtd., Ionis Pharmaceuticals Inc., Eli Lilly And Company, Merck & Co. Inc., Pfizer Inc., AstraZeneca, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Bayer AG, Allergan, Antares Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. GENITOURINARY DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Indication
  • 3.7.2 Market Attractiveness Analysis By Product
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY INDICATION

• 5.1. Overview By Indication
• 5.2. Historical and Forecast Data Analysis By Indication
• 5.3. Prostate Cancer Historic and Forecast Sales By Regions
• 5.4. Ovarian Cancer Historic and Forecast Sales By Regions
• 5.5. Bladder Cancer Historic and Forecast Sales By Regions
• 5.6. Cervical Cancer Historic and Forecast Sales By Regions
• 5.7. Renal Cancer Historic and Forecast Sales By Regions
• 5.8. Erectile Dysfunction Historic and Forecast Sales By Regions
• 5.9. Urinary Tract Infections Historic and Forecast Sales By Regions
• 5.10. Urinary Incontinence & Overactive Bladder Historic and Forecast Sales By Regions
• 5.11. Sexually Transmitted Diseases Historic and Forecast Sales By Regions
• 5.12. Interstitial Cystitis Historic and Forecast Sales By Regions
• 5.13. Haematuria Historic and Forecast Sales By Regions
• 5.14. Benign Prostatic Hyperplasia Historic and Forecast Sales By Regions

6. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY PRODUCT

• 6.1. Overview By Product
• 6.2. Historical and Forecast Data Analysis By Product
• 6.3. Urologicals Historic and Forecast Sales By Regions
• 6.4. Hormonal Therapy Historic and Forecast Sales By Regions
• 6.5. Gynecological Historic and Forecast Sales By Regions
• 6.6. Anti-Infectives Historic and Forecast Sales By Regions
• 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL GENITOURINARY DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE GENITOURINARY DRUGS COMPANIES

• 8.1. Genitourinary Drugs Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF GENITOURINARY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Abbott
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Bristol-Myers Squibb Co.
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. Novartis AG
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Genentech Inc.
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. F. Hoffmann-La RocheLtd.
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. Ionis Pharmaceuticals Inc.
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. Eli Lilly And Company
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. Merck & Co. Inc.
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. Pfizer Inc.
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments
• 9.12. AstraZeneca
  • 9.12.1 Company Overview
  • 9.12.2 Company Revenue
  • 9.12.3 Products
  • 9.12.4 Recent Developments
• 9.13. GlaxoSmithKline
  • 9.13.1 Company Overview
  • 9.13.2 Company Revenue
  • 9.13.3 Products
  • 9.13.4 Recent Developments
• 9.14. Teva Pharmaceutical Industries Ltd.
  • 9.14.1 Company Overview
  • 9.14.2 Company Revenue
  • 9.14.3 Products
  • 9.14.4 Recent Developments
• 9.15. Bayer AG
  • 9.15.1 Company Overview
  • 9.15.2 Company Revenue
  • 9.15.3 Products
  • 9.15.4 Recent Developments
• 9.16. Allergan
  • 9.16.1 Company Overview
  • 9.16.2 Company Revenue
  • 9.16.3 Products
  • 9.16.4 Recent Developments
• 9.17. Antares Pharma
  • 9.17.1 Company Overview
  • 9.17.2 Company Revenue
  • 9.17.3 Products
  • 9.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies